1. Home
  2. IDR vs LCTX Comparison

IDR vs LCTX Comparison

Compare IDR & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Idaho Strategic Resources Inc.

IDR

Idaho Strategic Resources Inc.

HOLD

Current Price

$38.02

Market Cap

378.0M

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.72

Market Cap

393.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDR
LCTX
Founded
1996
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
378.0M
393.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
IDR
LCTX
Price
$38.02
$1.72
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$17.50
$4.25
AVG Volume (30 Days)
425.5K
2.2M
Earning Date
11-12-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
52.70
N/A
EPS
0.73
N/A
Revenue
$35,424,313.00
$10,816,000.00
Revenue This Year
$21.91
$5.24
Revenue Next Year
$5.47
$126.78
P/E Ratio
$52.74
N/A
Revenue Growth
61.35
24.05
52 Week Low
$9.67
$0.37
52 Week High
$54.70
$2.09

Technical Indicators

Market Signals
Indicator
IDR
LCTX
Relative Strength Index (RSI) 55.63 49.89
Support Level $31.22 $1.57
Resistance Level $39.88 $1.76
Average True Range (ATR) 3.18 0.10
MACD 0.50 -0.01
Stochastic Oscillator 68.52 46.97

Price Performance

Historical Comparison
IDR
LCTX

About IDR Idaho Strategic Resources Inc.

Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: